Author Held, Gerhard

1 to 20 of 44 Items

2002 | Conference Abstract
Significant dose escalation of the CHOEP regimen in young patients with aggressive non Hodgkin's lymphoma is feasible: Results of a prospective randomized phase I/II trial.
Truemper, L. H.; Kloss, M.; Held, G.; Schmits, R.; Franke, A.; Berdel, W. E. & Fischer, T. et al. (2002)
Blood, 100(11) 44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA.
Washington: Amer Soc Hematology.
Details WoS

2011 | Conference Abstract
Allogeneic stem cell transplantation for patients with relapsed or chemorefractory T-cell lymphoma
Wulf, G. G.; Hasenkamp, J.; Jung, W.; Wilhelm, C.; Held, G.; Nickelsen, M. & Pfreundschuh, M. et al. (2011)
Onkologie, 34
Basel: Karger.
Details WoS

2011 | Conference Abstract
6-year follow-up of the mint study suggests a role for radiotherapy to bulky disease
Held, G.; Kuhnt, E.; Truemper, L. H.; Osterborg, A.; Trneny, M.; Shepherd, L. & Gill, D. S. et al. (2011)
Onkologie, 34
Basel: Karger.
Details WoS

2011 | Journal Article
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Kroenke, J.; Schlenk, R. F.; Jensen, K.-O.; Tschuertz, F.; Corbacioglu, A.; Gaidzik, V. I. & Paschka, P. et al. (2011)
Journal of Clinical Oncology, 29(19) pp. 2709-2716. DOI: https://doi.org/10.1200/JCO.2011.35.0371
Details DOI PMID PMC WoS

2012 | Journal Article
TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
Gaidzik, V. I.; Paschka, P.; Spaeth, D.; Habdank, M.; Koehne, C.-H.; Germing, U. & von Lilienfeld-Toal, M. et al. (2012)
Journal of Clinical Oncology, 30(12) pp. 1350-1357. DOI: https://doi.org/10.1200/JCO.2011.39.2886
Details DOI PMID PMC WoS

2014 | Conference Abstract
ALL-TRANS RETINOIC ACID AS ADJUNCT TO INTENSIVE TREATMENT IN YOUNGER ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA - FINAL RESULTS OF THE AMLSG 07-04 RANDOMIZED TREATMENT TRIAL
Schlenk, R. F.; Doehner, K.; Krauter, J.; Gaidzik, V. I.; Paschka, P.; Heuser, M. & Thol, F. et al. (2014)
Haematologica, 99 19th Congress of the European-Hematology-Association, Milan, ITALY.
Pavia: Ferrata Storti Foundation.
Details WoS

2014 | Conference Abstract
ACUTE MYELOID LEUKEMIA WITH RUNX1 MUTATIONS CONSTITUTE A DISTINCT ENTITY ASSOCIATED WITH CHARACTERISTIC CLINICAL AND GENETIC FEATURES AND POOR OUTCOME. A STUDY OF THE AML STUDY GROUP (AMLSG)
Gaidzik, V. I.; Teleanu, V.; Schlenk, R. F.; Spaeth, D.; Paschka, P.; Hahn, J. & Koehne, C.-H. et al. (2014)
Haematologica, 99 19th Congress of the European-Hematology-Association, Milan, ITALY.
Pavia: Ferrata Storti Foundation.
Details WoS

2014 | Conference Abstract
IMPACT OF THE COMPOSITION OF SALVAGE REGIMENS ON RESPONSE AND OVERALL SURVIVAL IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA
Wattad, M.; Doehner, K.; Krauter, J.; Gaidzik, V. I.; Paschka, P.; Heuser, M. & Thol, F. et al. (2014)
Haematologica, 99 19th Congress of the European-Hematology-Association, Milan, ITALY.
Pavia: Ferrata Storti Foundation.
Details WoS

2014 | Conference Abstract
Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
Kuchenbauer, F.; Bunjes, D. W.; Herr, W.; Heuser, M.; Spaeth, D.; Casper, J. & Horst, H. A. et al. (2014)
Blood, 124(21) 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA.
Washington: Amer Soc Hematology.
Details WoS

2014 | Conference Abstract
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+B-cell lymphomas: The SEXIE-R-CHOP-14 trial of the DSHNHL
Held, G.; Murawski, N.; Zeynalova, S.; Zwick, C.; Haenel, M.; Truemper, L. H. & Dreyling, M. et al. (2014)
Oncology Research and Treatment, 37
Basel: Karger.
Details WoS

2014 | Journal Article
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
Pfreundschuh, M.; Poeschel, V.; Zeynalova, S.; Haenel, M.; Held, G.; Schmitz, N. & Viardot, A. et al. (2014)
Journal of Clinical Oncology, 32(36) pp. 4127-U354. DOI: https://doi.org/10.1200/JCO.2013.54.6861
Details DOI PMID PMC WoS

2014 | Journal Article
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Schlenk, R. F.; Kayser, S.; Bullinger, L.; Kobbe, G.; Casper, J.; Ringhoffer, M. & Held, G. et al. (2014)
Blood, 124(23) pp. 3441-3449. DOI: https://doi.org/10.1182/blood-2014-05-578070
Details DOI PMID PMC WoS

2014 | Journal Article
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
Murawski, N.; Pfreundschuh, M.; Zeynalova, S.; Poeschel, V.; Haenel, M.; Held, G. & Schmitz, N. et al. (2014)
Annals of Oncology, 25(9) pp. 1800-1806. DOI: https://doi.org/10.1093/annonc/mdu208
Details DOI PMID PMC WoS

2014 | Journal Article
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Tassara, M.; Doehner, K.; Brossart, P.; Held, G.; Goetze, K. S.; Horst, H.-A. & Ringhoffer, M. et al. (2014)
Blood, 123(26) pp. 4027-4036. DOI: https://doi.org/10.1182/blood-2013-12-546283
Details DOI PMID PMC WoS

2014 | Journal Article | Letter Note
Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens
Hohloch, K.; Zeynalova, S.; Held, G.; Ziepert, M.; Loeffler, M.; Wulf, G. & Schmitz, N. et al. (2014)
Leukemia, 28(11) pp. 2260-2263. DOI: https://doi.org/10.1038/leu.2014.213
Details DOI PMID PMC WoS

2015 | Conference Abstract
Liposomal formulation of vincristine allows for doubling the dose compared to conventional vincristine: Results of the first futility analysis of the OPTIMAL > 60 study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Duecker, S.; Poeschel, V.; Wolf, A.; Held, G.; Murawski, N.; Zwick, C. & Haenel, M. et al. (2015)
Oncology Research and Treatment, 38 pp. 197-198.
Basel: Karger.
Details WoS

2015 | Conference Abstract
Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606)
Schlenk, R. F.; Doehner, K.; Salih, H. R.; Kuendgen, A.; Fiedler, W.; Salwender, H.-J. & Westermann, J. et al. (2015)
Blood, 126(23) 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL.
Washington: Amer Soc Hematology.
Details WoS

2016 | Journal Article
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial
Schlenk, R. F.; Fiedler, W.; Salih, H. R.; Wulf, G. ; Thol, F.; Kündgen, A. & Kindler, T. et al. (2016)
Blood, 128(22) pp. 449-449. DOI: https://doi.org/10.1182/blood.V128.22.449.449
Details DOI

2016 | Journal Article |
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
Schlenk, R. F.; Luebbert, M.; Benner, A.; Lamparter, A.; Krauter, J.; Herr, W. & Martin, H. et al. (2016)
Annals of Hematology, 95(12) pp. 1931-1942. DOI: https://doi.org/10.1007/s00277-016-2810-z
Details DOI PMID PMC WoS

2016 | Journal Article | Letter Note
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group
Theis, F.; Corbacioglu, A.; Gaidzik, V. I.; Paschka, P.; Weber, D.; Bullinger, L. & Heuser, M. et al. (2016)
Leukemia, 30(11) pp. 2248-2250. DOI: https://doi.org/10.1038/leu.2016.185
Details DOI PMID PMC WoS

Researcher

Göttingen All

Sort

issue date

ASC DESC

Items per Page

10 20 50 100